Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.5 USD | +0.22% | +15.98% | -51.66% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 381M |
---|---|---|---|---|---|
Net income 2024 * | -43M | Net income 2025 * | -56M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-8.65
x | P/E ratio 2025 * |
-7.03
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.95% |
Latest transcript on Anavex Life Sciences Corp.
1 day | +0.22% | ||
1 week | +21.29% | ||
Current month | +23.29% | ||
1 month | +6.38% | ||
3 months | -22.81% | ||
6 months | -27.18% | ||
Current year | -51.66% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 15-09-30 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Tom Skarpelos
FOU | Founder | 57 | 04-01-22 |
Jiong Ma
CHM | Chairman | 60 | 21-05-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 4.5 | +0.22% | 880,149 |
24-05-15 | 4.49 | +4.18% | 1,472,778 |
24-05-14 | 4.31 | +8.02% | 1,449,520 |
24-05-13 | 3.99 | +4.72% | 1,105,719 |
24-05-10 | 3.81 | -1.80% | 887,093 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.66% | 380M | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- AVXL Stock